Prostate stroma: Physiology

Prostate

Volumn 38, Issue 1, 1999, Pages 60-72

  Farnsworth, Wells E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Androgen; Constriction; Estrogen; Hyperplasia; Neovascularization; Secretion

Indexed keywords

ANDROGEN; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; ENDOTHELIN; EPIDERMAL GROWTH FACTOR; ESTROGEN; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; NITRIC OXIDE; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN RECEPTOR;

ANATOMY; ANGIOGENESIS; CELL PROLIFERATION; GLYCOLYSIS; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; REVIEW; SMOOTH MUSCLE CONTRACTION; STROMA CELL;

CYTOKINES; ENDOTHELINS; HUMANS; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; PROSTATE; STEROIDS; STROMAL CELLS;

EID: 0032893404     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990101)38:1<60::AID-PROS8>3.0.CO;2-3     Document Type: Review

References (105)

1. Farnsworth WE. Figuring out why we breathe. Med Hypotheses 1997;48:229-236.
2. Franks LM. A comparative study of the ultrastructure and lack of growth capacity of adult human prostate epithelium mechanically separated from its stroma. J Pathol 1970;100:113-119.
3. Cunha GR, Chung LWK, Shannon JM, Reese BA. Stromalepithelial interactions in sex differentiation. Biol Reprod 1980; 22:19-42.
4. Tenniswood M. Role of epithelial-stromal interactions in the control of gene expression in the prostate: An hypothesis. Prostate 1986;9:375-385.
5. Lee C. Biology of the prostate ductal system. In: Naz RK, editor. Prostate: Basic and Clinical Aspects. Boca Raton: CRC Press; 1997. p 53-71.
6. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y. The endocrinology and developmental biology of the prostate. Endocr Rev 1987;8:338-362.
7. Culig Z, Hobisch A, Cronauer MV, Radmayer C, Trapman J, Hittmaier A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-5478.
8. Steiner MS. Role of peptide growth factors in the prostate: A review. Urology 1993;42:99-110.
9. Bonkhoff H, Stein U, Remberger K. Multidirectional differentiation in the normal, hyperplastic and neoplastic prostate: Simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994;25:42-46.
10. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model. Prostate 1996;28:98-106.
11. Prins GS, Cooke PS, Birch L, Donjacour AA, Yaleinkaya TM, Siiteri PK, Cunha GR. Androgen receptor expression and 5α-reductase activity along the proximal-distal axis of the rat prostatic duct. Endocrinology 1992;130:3066-3073.
12. Tannenbaum M, Olsson CA. Surgical pathology of benign prostatic hyperplasia. In: Hinman F Jr, editor. Benign Prostatic Hypertrophy. New York Springer-Verlag; 1983. p 63-72.
13. Franks LM. Origins of benign prostatic hypertrophy. In: Hinman F Jr, editor. Benign Prostatic Hypertrophy. New York: Springer-Verlag; 1983. p 141-144.
14. McNeal JE. Relationship of the origin of benign prostatic hypertrophy to prostatic structure of man and other mammals. In: Hinman F Jr, editor. Benign Prostatic Hypertrophy. New York: Springer-Verlag; 1983. p 152-166.
15. Peehl DM, Sellers RG. Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp Cell Res 1997;232:208-215.
16. Kooistra A, Romijn JC, Schroder FH. Stromal inhibition of epithelial growth in the prostate; an overview of an experimental study. Urol Res [Suupl] 1997;51:97-105.
17. Larsen M, Ressler SJ, Lu B, Gerdes MJ, McBride L, Dang TD, Rowley DR. Molecular cloning and expression of ps20 growth inhibitor. A novel WAP-type "four-disulfide core" domain protein expressed in smooth muscle. J Biol Chem 1998;273: 4574-4584.
18. Byrne RL, Leung H, Meal DE. Peptide growth factors in the prostate as mediators of stromal-epithelial interaction. Br J Urol 1996;77:627-633.
19. Gann PH, Chatterton R, Vogelsong K, Grayhack JT, Lee C. Epidermal growth factor-related peptides in human prostateic fluid: Sources of variability in assay results. Prostate 1997;32: 234-240.
20. Tennant MK, Thrasher JB, Twomey PA, Birnbaum RS, Plymate SR. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 1996;81:411-420.
21. Boudon C, Rodier G, Lechevallier E, Mottet N, Barenton B, Sultan C. Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. J Clin Endocrinol Metab 1996;81:612-617.
22. Cohen P, Peehl DM, Rosenfeld RG. The IGF axis in the prostate. Metab Res 1994;26:81-84.
23. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801-809.
24. Tennant MK, Thrasher JB, Twomey PA. Protein and messenger ribonucleic acid (mRNA) for type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996;81:3774-3782.
25. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 1997;18:26-45.
26. Ittman M, Mansukhani A. Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. J Urol 1997; 157:353-356.
27. Van G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL. Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial cell andromedin. Mol Endocrinol 1992;6: 2123-2128.
28. Nemeth JH, Zelner DJ, Lang S, Lee C. Keratinocyte growth factor in ventral prostate: Androgen-independent expression. J Endocrinol 1998;156:115-125.
29. Sugimura Y, Foster BA, Horn YK, Lipschutz JH, Rubin JS, Finch PW, Aaronson SA, Hayashi N, Kawamura J, Cunha GR. Keratinocyte growth factor (KGF) can replace testosterone in the ductal branching morphogenesis of the rat ventral prostate. Int J Dev Biol 1996;40:941-951.
30. Thomson AA, Foster BA, Cunha GR. Analysis of growth factor and receptor mRNA levels during development of the rat seminal vesicle and prostate. Development 1997;124:2431-2439.
31. Bacher M, Rausch U, Goebel H-W, Polzar B, Mannherz HG, Aumuller G. II. Stromal and epithelial cells from rat ventral prostate during androgen deprivation and estrogen treatment - Regulation of transcription. Exp Clin Endocrinol 1993; 101:78-86.
32. Collins AT, Zhiming B, Gilmore K, Neal DE. Androgen and oestrogen responsiveness of stromal cells derived from the human hyperplastic prostate: Oestrogen regulation of the androgen receptor. J Endocrinol 1994;143:269-277.
33. Martikainen PM, Kypriano N, Isaacs JT. Effect of transforming growth factor on proliferation and death of rat prostatic cells. Endocrinology 1990;127:2963-2968.
34. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-10934.
35. Casey R, Li WW. Factors controlling ocular angiogenesis. Am J Ophthalmol 1997;124:521-529.
36. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Cancer Res 1996;69:135-174.
37. Campbell SC. Advances in angiogenesis research: Relevance to urological oncology. J Urol 1997;158:1663-1674.
38. Montironi R, Diamanti L, Thompson D, Bartels HG, Bartels PH. Analysis of the capillary architecture in the precursors of prostate cancer: Recent findings and new concepts. Eur Urol 1996;30:191-200.
39. Barren ESG, Huggins C. The Metabolism of isolated prostate tissue. J Urol 1944;51:630-634.
40. Farnsworth WE. Prostate plasma membrane receptor: A hypothesis. Prostate 1991;19:329-3552.
41. Culic O, Gruwel MLH, Schrader J. Energy turnover of vascular endothelial cells. Am J Physiol 1997;273:205-213.
42. Folkman J, Klaagsbrun M. Angiogenic factors. Science 1987; 235:442-148.
43. Birkhoff JD. Natural history of benign prostatic hypertrophy. In: Hinman F Jr, editor. Benign Prostatic Hypertrophy. New York: Springer-Verlag; 1983. p 5-9.
44. Deering RE, Bigler SA, Brown M, Brawer MK. Microvascularity in benign prostatic hyperplasia. Prostate 1995;26:111-115.
45. Minchenko A, Bauer T, Salceda S, Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 1994;71:374-379.
46. Ferrara N, Davis-Smith T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
47. Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997;157:2323-2328.
48. Brown LF, Yeo K-T, Berse B, Morgentaler A, Dvorak HF, Rosen S. Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. J Urol 1995; 154:576-579.
49. Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994; 269:4355-4359.
50. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995;220:13333-13340.
51. Levy AR, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 1996;271:2746-2753.
52. pekala P, Marlow M, Heuvelman D, Connolly D. Regulation of hexose transport in aortic endothelial cells by vascular endothelial growth factor and tumor necrosis factor-alpha, but not by insulin. J Biol Chem 1990;265:18051-18054.
53. Joseph IB, Isaacs JT. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human and rogen-responsive prostatic cancers. Cancer Res 1997;57:1054-1057.
54. Nicosia R, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol 1994;145:1023-1029.
55. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992;189:824-831.
56. Weingärtner K, Ben-Sasson SA, Stewart R, Richie JP, Riedmiller H, Folkman J. Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: An in vitro model for assessment. J Urol 1998;159:465-470.
57. Bikfalvi A, Klein S, Pintucci G, Rilkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 1997;18:26-45.
58. Kuwabara K, Ogawa S, Matsumoto M, Koga S, Clauss M, Pinsky DJ, Lyn P, Leavy J, Witte L, Joseph-Silverstein J, Furie MB, Torcia G, Cozzolino F, Kamada T, Stern DM. Hypoxiamediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci USA 1995;92:4606-4610.
59. Kenny B, Ballard 5, Blagg J, Fox D. Pharmacological options in the treatment of benign prostatic hyperplasia. J Med Chem 1997;40:1298-1315.
60. Huggins C. The physiology of the prostate gland. Physiol Rev 1945;25:281-295.
61. Farnsworth WE, Lawrence MH. Regulation of prostatic secretion in the rat. Proc Soc Exp Biol Med 1965;119:373-376.
62. Jacobs SC, Story MT. Exocrine secretion of epidermal growth factor by the rat prostate: Effect of adrenergic agents, cholinergic agents, and vasoactive intestinal peptide. Prostate 1988; 13:79-87.
63. Wang J-M, McKenna KE, Lee C. Determination of prostatic secretion in rats: Effect of neurotransmitters and testosterone. Prostate 1991;18:289-301.
64. McVary KT, McKenna KE, Lee C. Prostate innervation. Prostate [Suppl] 1998;2-13.
65. Zwart R, Vijverberg HPM. Potentiation and inhibition of neuronal nicotinic receptors by atropine: Competitive and non-competitive effects. Mol Pharmacol 1997;52:886-895.
66. Huggins C. The prostatic secretion. Harvey Lect 1947;42:148-193.
67. Luthin GR, Wang P, Zhou H, Dhanasekaran D, Ruggieri MR. Role of M1 receptor-G protein in cell proliferation in the prostate. Life Sci 1997;60:963-968.
68. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostate capsule and bladder. Br J Urol 1975;47:193-202.
69. Andersson K-E, Lepor H, Wyllie MG. Prostatic α-adrenoceptors and uroselectivity. Prostate 1997;30:202-215.
70. Guh J-H, Ko F-N, Chueh S-C, Lai M-K, Teng C-M. Ouabain-induced increases in resting tone of human hyperplastic prostate following repeated noradrenaline and electric field stimulation. Br J Pharmacol 1996;117:1716-1720.
71. +-ATPase in rat arterial smooth muscle. Am J Physiol 1997;273:113-121.
72. Ruggieri MR, Colton MD, Wang P, Wang J, Smyth RJ, Pontari MH, Luthin GR. Human prostate muscarinic receptor subtypes. J Pharmacol Exp Ther 1995;274:976-982.
73. Gutkind JS, Novotny EA, Brann MR, Robbins KC. Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. Proc Natl Acad Sci USA 1991;88:4703-4707.
74. Smyth RJ. The role of muscarinic cholinergic receptors in human prostate adenocarcinoma cell proliferation. Ph.D. dissertation. Ann Arbor, MI: University of Michigan;University Microfilms International UMI number 9535806, 1995.
75. Levin ER. Endothelins as cardiovascular peptides. Am J Nephrol 1996;16:246-251.
76. Rossi GP, Albertini G, Franchin E, Sacchetto A, Cesari M, Palu G, Pessina AC. Expression of the endothelin-converting enxyme gene in human tissues. Biochem Biophys Res Commun 1995;211:249-253.
77. Yanagisawa M, Kurihara H, Kimura S, Tiomobe Y, Kobayati M, Mitsui Y, Yasaki Y, Goto G, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-416.
78. Langenstroer P, Tang R, Shapiro E, Divish B, Opgenorth T, Lepor H. Endothelin-1 in the human prostate: Tissue levels, source of production and isometric tension studies. J Urol 1993; 149:495-499.
79. LeBrun G, Moldovan F, Aubin P, Ropiquet F, Cussenot O, Fiet J. Identification of endothelin receptors in normal and hyperplastic human prostate tissues. Prostate 1996;28:379-384.
80. Kobayashi S, Tang R, Wang B, Opgenorth T, Stein E, Shapiro E, Lepor H. Localization of endothelin receptors in the human prostate. J Urol 1994;151:763-766.
81. Webb ML, Chao CC, Rizzo M, Shapiro RA, Neubauer M, Liu CC, Aversa CR, Brittain RJ, Treiger B. Cloning and expression of endothelin receptor subtype B from human prostate that mediates contraction. Mol Pharmacol 1995;17:730-737.
82. Dhanasekaran N, Heasley LE, Johnson GL. G protein-coupled receptor systems involved in cell growth and oncogenesis. Endoer Rev 1995;16:259-270.
83. Battistini B, Chailler P, D'Orleans-Juste P, Brière N, Sirois P. Growth regulatory properties of endothelins. Peptides 1993;14: 385-399.
84. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, Simons JVV. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996;56:663-668.
85. Prayer-Galetti T, Rossi GP, Belloni AS, Albertin G, Battanello W, Piovan V, Gardiman M, Pagano F. Gene expression and autoradiographic localization of endothelin-1 and its receptors A and B in the different zones of the normal human prostate. J Urol 1997;157:2334-2339.
86. McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol 1968;49:347-357.
87. B ET receptors by prostatic epithelium and stroma. J Clin Endocrinol Metab 1997;82:508-513.
88. Walden PD, Ittmann M, Monaco ME, Lepor H. Endothelin-1 production and agonist activities in cultured prostate-derived cells: Implications for regulation of endothelin bioactivity and bioavailability in prostatic hyperplasia. Prostate 1998;34:241-250.
89. Harrison DG. Nitric oxide and nitric oxide synthases. J Clin Invest 1997;100:2153-2157.
90. Muniyappa R, Walsh JS, Rangi JS, Zayas RM, Standley PR, Ram JL, Sowers JR. Insulin-like growth factor 1 increases vascular smooth muscle nitric oxide production. Life Sci 1997;61: 925-931.
91. Ziche M, Morbidelli L, Choudhuri R, Zhang H-T, Donnini S, Granger HT, Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997;99:2625-2634.
92. Papapetropoulos A, Garcia-Gardeña G, Madri JA, Sessa WC. Nitric oxide production contributes to angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997;100:3131-3139.
93. Burnett AL, Macguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H, Chang TSK. Characterization and localization of nitric oxide synthase in the human prostate. Urology 1995;45: 435-439.
94. Guate JL, Escaf S, Menendez CL, del Valle M, Vega JA. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: Effect of hormonal treatment. Urol Int 1997;59:149-153.
95. Lin AT-L, Chen M-T, Chiang H, Yang C-H, Chang LS. Effect of orchiectomy on the alpha adrenergic contractile response of dog prostate. J Urol 1995;154:1930-1933.
96. Holmquist F, Persson K, Bodker A, Andersson K-E. Some pre-and postjunctional effects of castration: Rabbit isolated corpus cavernosus and urethra. J Urol 1994;152:1011-1016.
97. Darkow DJ, Lu L, White RE. Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. Am J Physiol 1997;272:2765-2773.
98. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogens. FASEB J 1996;10:615-624.
99. Freay AD, Curtis SW, Korach KJ, Rubanyi GM. Mechanism of vascular smooth muscle relaxation by estrogen in depolarized rat and mouse aorta. Role of nuclear estrogen receptor and Ca2+ uptake. Circ Res 1997;81:242-248.
100. Wingrove CS, Stevenson JC. 17β-oestradiol inhibits stimulated endothelin release in human vascular endothelial cells. Eur J Endocrinol 1997;137:205-208.
101. Espinosa E, Oemar BS, Luscher TF. 17β-estradiol and smooth muscle cell proliferation in aortic cells of male and female rats. Biochem Biophys Res Commun 1996;221:8-14.
102. Farnsworth WE. Roles of estrogen and SHBG in prostate physiology. Prostate 1996;28:17-23.
103. Ehara H, Koji T, Degushi T, Yoshii A, Nakano M, Nakano PK, Kawada Y. Expression of estrogen receptor in diseased human prostate assessed by nonradioactive in situ hybridization and immunohistochemistry. Prostate 1995;27:305-313.
104. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafasson J-Å. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997;138:863-870.
105. 2α in prostatic function. In: Murphy GP, Sandberg AA, Karr JP, editors. The prostate cell: structure and function. New York: Alan R. Liss, Inc.; 1981. p 225-230.